iPSC DIFFERENTIATION SERVICES FOR RESEARCHERS
DRIVING CELL BIOLOGY EVOLUTION THROUGH iPSC INNOVATION
Cost-effective pluripotent stem cells (iPSC) differentiation services with fast turnaround time for your research. Our protocols can be tailored from small to large scale production based on your needs. Upon request, our dedicated stem cell specialists will provide free consultation and ongoing support for your disease modeling studies.
WHAT OUR CLIENTS SAY ABOUT US
I have been working with the iXCells for many years, including a very fruitful collaboration with their team to generate iPSCs lines and neuronal differentiation for disease modeling. iXCells are experts in both gene editing services and neuronal differentiation methodologies. I have had a very positive experience working with their scientific team. Their assays to generate a set of CRISPR-edited isogenic iPSC lines were very efficient and productive. iXCells also developed an improved technology for neuronal differentiation, resulting in highly purified human cortical and motor neurons in a dish. I found it outstanding that I could simply thaw one of their frozen vials containing precursor motor neurons and rapidly receive matured neurons in culture. These could last over > 1 month, which demonstrates their high performance. Last, my experience with iXCells team was always very positive and supportive. Their professional team was always very kind and ready to help, and I really enjoyed working in close collaboration with them. I strongly recommend iXCells for both assay development and their great services and products.
Human iPSC-Motor Neuron Differentiation
Figure 1. Human iPSC-motor neuron differentiation. (A) Phase contrast image of iPSC before differentiation. Scale bar: 500 µm; (B) Neural spheres upon neural induction on Day 11. Scale bar: 200 µm;(C) Neural rosette formation in neural progenitor cells (NPCs). Scale bar: 100 µm; (D and E) The cryopreserved iPSC-derived motor neurons were recovered and cultured 200,000 viable cells in Motor Neuron Maintenance Medium on PDL / Cultrex-coated wells in the 48-well plate; (D) The cells were fixed and stained with anti-HB9 and anti-TUJ1 on Day 2 post thaw; (E) The cells were fixed and stained with anti-MAP2 and anti-ChAT on Day 7 post thaw. Scale bar: 100 µm.
Figure 2. Characterization of Human iPSC-motor neurons. (A and B) The iPSC-motor neurons were recovered and cultured in Motor Neuron Maintenance Medium for 2 days on Cultrex-coated plates, and then the cells were collected for FACS analysis with antibodies against TUJ1 and HB9; (C-E) The iPSC-motor neurons were recovered and cultured in Motor Neuron Maintenance Medium for 7 days on Cultrex-coated plates, and then the cells were collected for FACS analysis with antibodies against FOXP1, ISL1 and NeuN; (F) iPSC-MNs cell pellets were used for mycoplasma screening by PCR amplification of a ~270 bp sequence conserved in most of the mycoplasma species and a ~617 bp sequence conserved in most cells. Positive Ctl: DNA from a tested mycoplasma positive sample; Negative Ctl 1: Lysis buffer which was used to extract gDNA; Negative Ctl 2: DNA from a tested mycoplasma negative sample.
Liu B, Li M, Zhang L, Chen Z, Lu P. (2022). Motor neuron replacement therapy for amyotrophic lateral sclerosis. Neural Regen Res;17:1633-9 -- Learn More
Liu, Y., Dodart, J., Tran, H., Berkovitch, S., Braun, M., Byrne, M., . . . Brown, R. H. (2021). Variant-selective stereopure oligonucleotides protect against pathologies associated with c9orf72-repeat expansion in preclinical models. Nature Communications, 12(1). doi:10.1038/s41467-021-21112-8 -- Learn More
Osaki, T., Uzel, S. G., & Kamm, R. D. (2020). On-chip 3d neuromuscular model for drug screening and precision medicine in neuromuscular disease. Nature Protocols, 15(2), 421-449. doi:10.1038/s41596-019-0248-1 -- Learn More
Shen, X., Beasley, S., Putman, J. N., Li, Y., Prakash, T. P., Rigo, F., . . . Corey, D. R. (2019). Efficient electroporation of neuronal cells using synthetic oligonucleotides: Identifying duplex RNA and antisense oligonucleotide activators of Human frataxin expression. RNA, 25(9), 1118-1129. doi:10.1261/rna.071290.119 -- Learn More
Gasset-Rosa, F., Lu, S., Yu, H., Chen, C., Melamed, Z., Guo, L., . . . Cleveland, D. W. (2019). Cytoplasmic TDP-43 de-mixing independent of stress granules drives inhibition of nuclear import, loss of nuclear TDP-43, and cell death. Neuron, 102(2). doi:10.1016/j.neuron.2019.02.038 -- Learn More
Martier, R., Liefhebber, J. M., García-Osta, A., Miniarikova, J., Cuadrado-Tejedor, M., Espelosin, M., . . . Konstantinova, P. (2019). Targeting rna-mediated toxicity in c9orf72 als and/or ftd by rnai-based gene therapy. Molecular Therapy - Nucleic Acids, 16, 26-37. doi:10.1016/j.omtn.2019.02.001 -- Learn More
Melamed, Z., López-Erauskin, J., Baughn, M. W., Zhang, O., Drenner, K., Lin, N., Wu, D., . . . Cleveland, D. W. (2019). Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of tdp-43-dependent neurodegeneration. Nature Neuroscience, 22(2), 180-190. doi:10.1038/s41593-018-0293-z -- Learn More
- Marei, H. E., Althani, A., Lashen, S., Cenciarelli, C., & Hasan, A. (2017). Genetically unmatched human Ipsc and Esc Exhibit Equivalent gene expression and neuronal differentiation potential. Scientific Reports, 7(1). doi:10.1038/s41598-017-17882-1 -- Learn More
Osaki, T., Uzel, S. G., & Kamm, R. D. (2018). Microphysiological 3D model of amyotrophic lateral sclerosis (ALS) from human iPS-derived muscle cells and optogenetic motor neurons. Science Advances, 4(10). doi:10.1126/sciadv.aat5847 -- Learn More
Danziger, S. A., Miller, L. R., Singh, K., Whitney, G. A., Peskind, E. R., Li, G., . . . Smith, J. J. (2017). An indicator cell assay for blood-based diagnostics. PLOS ONE, 12(6). doi:10.1371/journal.pone.0178608 -- Learn More
FREQUENTLY ASKED QUESTIONS (FAQs)
Please provide the project information in the inquiry form, including but not limited to starting cells, desired differentiated cell type, scale of differentiation, specific markers of interest and any functional assay of interest.
Cells to be differentiated: Ideally 2-3 vials of frozen stocks on dry ice or one T25 flask of live cells per sample. iXCells also provides a wide collection of iPSCs for the customers to choose from.
The customer should provide pathogen screening result for the starting materials. If not, iXCells Biotechnologies will perform the pathogen screening with additional costs.
iXCells provides a wide collection of iPSCs from normal or diseased donors.
We also help our customers to get access to the iPSC repositories, such as Coriell Institute, NINDS, etc..
In addition, we help our customer to develop their own iPSC models with our Reprogramming and Genome Editing services.
Contact us to learn more about generating your own lines or sourcing iPSC lines of interest.
It takes 2-3 months depending on the recovery of the cells provided by the customer, cell type to be differentiated, and the scale of differentiation.
Yes, please Contact us to learn more about in vitro assays provided by iXCells, including neurite outgrowth, electrophysiological analysis, toxicology test, image-based assays, etc..
- Cryovials of differentiated cells or live culture for cell types not suitable for cryopreservation.
- Culture medium for differentiated cells
- Reports and data: raw data and analyzed data in publication-ready format
iPSC GENERATION SERVICES
Induced Pluripotent Stem Cells (iPSCs) engineering to advance drug discovery, drug screening, disease modeling, personalized medicine, and preclinical cell regeneration projects.
ANTISENSE OLIGONUCLEOTIDE (ASO) SCREENING SERVICES
Integrated Drug Discovery Services with Patient-Specific Disease Models for N-of-1 Solution